We are live on ! Find out more
RXRX icon

Recursion Pharmaceuticals
RXRX

84 hedge funds and large institutions have $1.26B invested in Recursion Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 43 increasing their positions, 11 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

291% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 11

248% more call options, than puts

Call options by funds: $1.48M | Put options by funds: $425K

143% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 7

12% more funds holding

Funds holding: 75 → 84 (+9)

6.63% more ownership

Funds ownership: 27.91% → 34.53% (+6.6%)

26% less capital invested

Capital invested by funds: $1.71B → $1.26B (-$451M)

33% less funds holding in top 10

Funds holding in top 10: 6 → 4 (-2)

Holders
84
Holders Change
+9
Holders Change %
+12%
% of All Funds
1.47%
Holding in Top 10
4
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-33.33%
% of All Funds
0.07%
New
17
Increased
43
Reduced
11
Closed
7
Calls
$1.48M
Puts
$425K
Net Calls
+$1.05M
Net Calls Change
+$349K

Top Buyers

Rank Fund Capital Flow
1
Baillie Gifford & Co
Baillie Gifford & Co
United Kingdom
+$100M
2
State Street
State Street
Massachusetts
+$35.9M
3
Mitsubishi UFJ Trust & Banking
Mitsubishi UFJ Trust & Banking
Japan
+$11.3M
4
YRHAM
Yong Rong (HK) Asset Management
Hong Kong
+$10.7M
5
AllianceBernstein
AllianceBernstein
Tennessee
+$9.62M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$7.13M
2
Massachusetts Financial Services
Massachusetts Financial Services
Massachusetts
-$2.27M
3
RCM
Ratan Capital Management
Florida
-$2.12M
4
BG
Bellevue Group
Switzerland
-$730K
5
SB
Samsara BioCapital
California
-$642K
Name Holding Trade Value Shares
Change 		Change in
Stake
YRHAM
26
Yong Rong (HK) Asset Management
Hong Kong
$8.68M +$10.7M +377,000 New
NAMA
27
Nikko Asset Management Americas
New York
$8.59M +$4.91M +173,348 +74%
PCM
28
Pentwater Capital Management
Florida
$6.1M +$354K +12,500 +5%
DFO
29
Duquesne Family Office
New York
$5.98M +$7.37M +259,941 New
Northern Trust
30
Northern Trust
Illinois
$5.77M +$235K +8,295 +3%
AG
31
Artal Group
Luxembourg
$4.6M – – –
Charles Schwab
32
Charles Schwab
California
$4.21M +$507K +17,891 +11%
TRSOTSOK
33
Teachers Retirement System of the State of Kentucky
Kentucky
$3.78M +$2.26M +79,659 +94%
American Century Companies
34
American Century Companies
Missouri
$3.48M +$4.29M +151,359 New
Susquehanna International Group
35
Susquehanna International Group
Pennsylvania
$2.7M +$1.89M +66,614 +132%
N
36
Nuveen
North Carolina
$2.46M +$373K +13,153 +17%
Bank of New York Mellon
37
Bank of New York Mellon
New York
$2.39M +$868K +30,633 +42%
HI
38
HBK Investments
Texas
$2.3M – – –
UBS Group
39
UBS Group
Switzerland
$1.64M +$2M +70,443 +10,063%
AO
40
Allen Operations
New York
$1.57M – – –
Rafferty Asset Management
41
Rafferty Asset Management
New York
$1.56M +$1.93M +68,021 New
SRAM
42
Spouting Rock Asset Management
Pennsylvania
$1.22M +$1.5M +52,851 New
Citigroup
43
Citigroup
New York
$1.04M +$1.26M +44,288 +4,402%
TD Asset Management
44
TD Asset Management
Ontario, Canada
$935K – – –
RCM
45
Ratan Capital Management
Florida
$807K -$2.12M -74,931 -68%
JP Morgan Chase
46
JP Morgan Chase
New York
$727K +$329K +11,611 +58%
Russell Investments Group
47
Russell Investments Group
United Kingdom
$725K – – –
CSS
48
Cubist Systematic Strategies
Connecticut
$637K +$399K +14,086 +104%
State of Wisconsin Investment Board
49
State of Wisconsin Investment Board
Wisconsin
$628K – – –
Bank of America
50
Bank of America
North Carolina
$610K +$528K +18,630 +237%
1
2
3 4

RXRX Hedge Fund Activity: Q3 2021 in Review

84 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Recursion Pharmaceuticals (RXRX) for Q3 2021, worth a combined $1.26B — down 26% from $1.71B a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new RXRX positions and 7 closed out — a net gain of 10 holders — while 43 added to existing stakes and 11 trimmed.

The largest buyer was Baillie Gifford & Co, adding an estimated $100M. The largest seller was Fidelity Investments, cutting an estimated $7.13M.

  • 84 institutional investors held Recursion Pharmaceuticals (RXRX) as of Q3 2021, up from 75 in Q2 2021.
  • Funds reported $1.26B of Recursion Pharmaceuticals stock for Q3 2021, down 26% quarter-over-quarter.
  • 17 funds opened new Recursion Pharmaceuticals positions in Q3 2021 and 7 closed out, a net change of +10 holders.
  • The largest Recursion Pharmaceuticals buyer in Q3 2021 was Baillie Gifford & Co, an estimated $100M added.
  • The largest Recursion Pharmaceuticals seller in Q3 2021 was Fidelity Investments, an estimated $7.13M sold.

Based on aggregated 13F filings for Q3 2021.